The underwriters exercised their option to purchase 1 million shares of common stock from the selling stakeholders at a price of $15 per share before underwriting discounts. The over-allotment option closed on June 10 and K2M will not receive any proceeds from the sale of these shares.
Pipar Jaffray & Co., Barclays Capital and Wells Fargo Securities acted as joint book-running managers for the offering. William Blair & Company and Cowen and Company acted as co-managers.
More Articles on Medical Devices:
5 Key Cost & Quality Findings on Spinal Fusion vs. coflex
Orthocell Launches IPO: 3 Key Facts
Behind the K2M IPO: CEO Eric Major Talks Strategy, Innovation & Future Financial Growth
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
